News

Trading Update and Notice of Results

March 26, 2021

Following the Company’s announcement on 25 January 2021 the Company has been progressing the year end audit and anticipates being able to announce the 2020 full year results on Thursday, 1 April 2021. The Directors of Proteome Sciences are pleased to announce that the Company now expects to report profit after tax materially higher than announced on 25 January.  This is primarily due to higher than expected royalty receipts from Thermo Scientific for the last quarter of 2020.  The annual results are still subject to finalisation of the audit and approval by the Board.

Proteome Sciences’ proprietary TMTcalibrator™ workflow for tissue-enhanced phosphoproteomics in Alzheimer’s disease CSF featured in new publication from Cognition Therapeutics, Inc

February 11, 2021

Proteome Sciences’ proprietary TMTcalibrator™ workflow for tissue-enhanced phosphoproteomics in Alzheimer’s disease CSF featured in new publication from Cognition Therapeutics, Inc. Results show that CT1812 treatment reduces levels of phosphorylation on CSF tau including at many sites only quantifiable using TMTcalibrator™. Citation: “Izzo NJ, Yuede CM, LaBarbera KM, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021;1-18. https://doi.org/10.1002/alz.12302

Year End Trading Update

January 25, 2021

The Company today provides a trading update for the financial year ended 31 December 2020.

Holding(s) in Company

January 18, 2021

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 15 January 2021.

Director/PDMR Shareholding

September 15, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 14 September 2020 it purchased 363,037 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.96p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,826,194 Ordinary Shares, equivalent to 22.30% of Proteome Sciences' total issued share capital.

Appointment of Chief Executive Officer

September 14, 2020

The Board of Proteome Sciences plc is pleased to announce that Dr. Mariola Söhngen has been appointed as a director and Chief Executive Officer and she will take up the position on September 15th, 2020. Dr Ian Pike remains a director of the Company as Chief Scientific Officer, having also fulfilled the role of Interim Chief Executive Officer until Dr Söhngen’s appointment.

Interim results for the six months ended 30 June 2020

August 10, 2020

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2020.

Holding(s) in Company

July 27, 2020

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 24 July 2020.

Director/PDMR Shareholding

July 07, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 3 July 2020 it purchased 99,999 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.90p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,463,157 Ordinary Shares, equivalent to 22.18% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding

July 02, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 30 June and 1 July 2020 it purchased 100,000 and 60,000 Ordinary Shares of 1p, respectively,  in the capital of the Company ("Ordinary Shares") at an average price of 3.95p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,363,158 Ordinary Shares, equivalent to 22.14% of Proteome Sciences' total issued share capital.